Developer docs
API playgroundTry for free, no card

Search company profiles

Alzheon

Full company profile

uuid0000mi7

Namestring
Alzheon
Legal namestring
Alzheon, Inc.
Websiteurl
alzheon.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Alzheon is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Framingham, Massachusetts, that is developing oral small-molecule disease-modifying treatments for Alzheimer's disease and other neurodegenerative disorders. Its lead asset, valiltramiprosate/ALZ-801, is a valine-conjugated prodrug of tramiprosate that uses a novel enveloping molecular mechanism to fully block formation of neurotoxic soluble beta amyloid oligomers without affecting insoluble plaques or fibrils. The program is supported by an internally discovered endogenous metabolite, 3-sulfopropanoic acid (3-SPA), which contributes to brain penetration and selectivity. A second oral candidate, ALZ-507, entered a Phase 1 trial in April 2026 with an APOE4 corrector mechanism and potential once-daily dosing.

The company employs a precision medicine strategy, initially targeting Early Alzheimer's disease patients homozygous for the APOE4/4 genotype (approximately 15% of AD patients), with planned expansion to APOE3/4 heterozygotes and to prevention settings. The pivotal APOLLOE4 Phase 3 trial enrolled 325 APOE4/4 homozygotes over 78 weeks in North America and Europe; topline results in April 2025 showed cognitive and functional benefit in prespecified analyses in the mild cognitive impairment subgroup, and full results were peer-reviewed in Drugs in October 2025. ALZ-801 has carried FDA Fast Track designation since 2017.

Alzheon's business model is currently pre-revenue and built around advancing its pipeline toward U.S. commercialization of ALZ-801 in 2025, supported by a $100 million Series E (June 2024), a prior $50 million Series D (April 2022), and $51 million in grants from the National Institute on Aging. The company is constructing a U.S. direct sales and market access organization under a newly appointed Chief Commercial Officer with prior launch experience at Biogen, Genentech, J&J, and AstraZeneca. Revenue mechanics will rely on prescription pharmaceutical sales to healthcare providers and payers once approval is secured; pricing has not been publicly disclosed and no licensing revenue has been reported.

Short descriptiontext

Alzheon is a clinical-stage biopharmaceutical company developing oral anti-amyloid oligomer small molecules, led by valiltramiprosate (ALZ-801) in Phase 3 for Early Alzheimer's disease in APOE4/4 homozygotes, preparing for a U.S. commercial launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFramingham, United States
HQ citystring
Framingham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Alzheimer's disease therapeutics, oral anti-amyloid drugs, neurodegenerative disease treatment, clinical-stage biopharmaceuticals, precision medicine pharmaceuticals
Product category
Alzheimer's Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Alzheon plans to commercialize oral valiltramiprosate/ALZ-801 as a disease-modifying treatment for Alzheimer's disease following regulatory approval. Expected commercial launch in 2025 pending successful Phase 3 trial completion and NDA submission.

vcaonline.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Alzheon is developing valiltramiprosate/ALZ-801, an investigational oral anti-amyloid oligomer treatment for Early Alzheimer's disease, with initial focus on APOE4/4 homozygote patients. The product blocks formation of neurotoxic soluble beta amyloid oligomers through a novel enveloping molecular mechanism of action without binding to amyloid plaques. The company has completed Phase 3 APOLLOE4 testing and is preparing for potential regulatory approval and U.S. commercial launch.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 31% reduction in plasma P-tau181 at 24 months in Phase 2 trial
+3 more records
Product overview1 text field

Alzheon is a clinical-stage biopharmaceutical company developing a portfolio of product candidates for Alzheimer's disease and other neurodegenerative disorders. The lead product is valiltramiprosate/ALZ-801, an oral anti-amyloid agent in Phase 3 development targeting neurotoxic beta amyloid oligomers in early Alzheimer's disease patients, particularly APOE4/4 homozygotes. The company also has ALZ-507 in Phase 1 development and maintains a discovery platform of small molecules using precision medicine approaches. The company is preparing for potential regulatory filings and commercialization of ALZ-801 with expected U.S. market launch in 2025.

Product and service2 records
1Valiltramiprosate/ALZ-801
CategoryAlzheimer's Disease Therapeutic (Oral Anti-Amyloid Oligomer Agent)
Description

Valiltramiprosate/ALZ-801 is an investigational first-in-class oral anti-amyloid agent that blocks formation of neurotoxic soluble beta amyloid oligomers through a novel enveloping molecular mechanism of action, without binding to amyloid plaques or causing vasogenic brain edema. It is being developed as a disease-modifying treatment for Early Alzheimer's disease, with initial focus on patients homozygous for the APOE4/4 genotype who are 8-12 times more likely to develop AD. The oral tablet formulation crosses the blood-brain barrier efficiently and enables convenient at-home administration.

2ALZ-507
CategoryAlzheimer's Disease Therapeutic (Next-Generation Oral Small Molecule)
Description

ALZ-507 is an oral drug candidate in Phase 1 development for Alzheimer's disease that targets amyloid aggregation with an additional APOE4 corrector mechanism. It is designed for potential once-daily administration with improved safety and efficacy compared to existing anti-amyloid therapies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or Integration
Description

ALZ-801/valiltramiprosate was licensed from Bellus Health. The drug is an optimized prodrug of tramiprosate originally developed by Bellus Health.

2Eisai
Strategic tierMinorTypeStrategic or Co-development Partner
Description

At the AD/PD annual meeting, both companies presented data on treatments targeting high-risk Alzheimer's patients with APOE4 genetic profiles. Both focus on improving treatment options for genetically defined populations.

biospace.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing protein immunotherapy approaches for Alzheimer's disease and other neurodegenerative disorders, including anti-amyloid antibodies. Comparable as a clinical-stage AD-focused biotech with overlapping target biology.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapeutics for Alzheimer's disease and neurodegenerative disorders, with both small molecule and vaccine approaches. Comparable as a clinical-stage AD biotech with multiple pipeline assets targeting amyloid and tau.

TypeEmerging player
Description

Clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases, with a focus on TREM2 agonist and microglia-targeting approaches. Comparable as an emerging clinical-stage neurodegeneration biotech with similar stage and target indication space.

TypeDirect peer
Description

Clinical-stage company developing CT1812, an oral small molecule for Alzheimer's disease and other neurodegenerative disorders. Comparable as a similarly-staged AD biotech focused on synaptic and oligomer-related mechanisms.

TypeBroad incumbent
Description

Large biopharmaceutical company with marketed Alzheimer's therapies including Aduhelm and co-developed Leqembi. Comparable as the established incumbent in the AD therapeutics space, against which Alzheon's oral therapy must differentiate.

TypeEmerging player
Description

Clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's, with a focus on small molecules and biologics that cross the blood-brain barrier. Comparable as an emerging clinical-stage CNS biotech with similar BBB-penetration and neurodegeneration focus.

TypeDirect peer
Description

Clinical-stage biotechnology company developing blarcamesine (ANAVEX2-73), an oral small molecule for Alzheimer's disease and other neurodegenerative disorders. Directly comparable as a clinical-stage CNS biotech with similar development profile and oral small molecule approach.

TypeBroad incumbent
Description

Global pharmaceutical company that markets Kisunla (donanemab) for early symptomatic Alzheimer's disease. Comparable as a broad incumbent in AD therapeutics with an approved anti-amyloid antibody competing with Alzheon's oral approach.

9Eisai
TypeBroad incumbent
Description

Global pharmaceutical company that co-developed and markets Leqembi (lecanemab) for Alzheimer's disease. Comparable as the leading commercialized AD therapeutics incumbent and a co-development partner cited in Alzheon's industry engagement.

10Cassava Sciences
TypeDirect peer
Description

Clinical-stage biotechnology company developing simufilam, an oral small molecule for Alzheimer's disease. Directly comparable to Alzheon as a similarly-sized private/public clinical-stage AD therapeutics company targeting oral disease-modifying mechanisms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alzheon

Alzheimer's Disease Therapeuticsalzheon.com

Alzheon is a clinical-stage biopharmaceutical company developing oral anti-amyloid oligomer small molecules, led by valiltramiprosate (ALZ-801) in Phase 3 for Early Alzheimer's disease in APOE4/4 homozygotes, preparing for a U.S. commercial launch.

What Alzheon does

Alzheon is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Framingham, Massachusetts, that is developing oral small-molecule disease-modifying treatments for Alzheimer's disease and other neurodegenerative disorders. Its lead asset, valiltramiprosate/ALZ-801, is a valine-conjugated prodrug of tramiprosate that uses a novel enveloping molecular mechanism to fully block formation of neurotoxic soluble beta amyloid oligomers without affecting insoluble plaques or fibrils. The program is supported by an internally discovered endogenous metabolite, 3-sulfopropanoic acid (3-SPA), which contributes to brain penetration and selectivity. A second oral candidate, ALZ-507, entered a Phase 1 trial in April 2026 with an APOE4 corrector mechanism and potential once-daily dosing.

The company employs a precision medicine strategy, initially targeting Early Alzheimer's disease patients homozygous for the APOE4/4 genotype (approximately 15% of AD patients), with planned expansion to APOE3/4 heterozygotes and to prevention settings. The pivotal APOLLOE4 Phase 3 trial enrolled 325 APOE4/4 homozygotes over 78 weeks in North America and Europe; topline results in April 2025 showed cognitive and functional benefit in prespecified analyses in the mild cognitive impairment subgroup, and full results were peer-reviewed in Drugs in October 2025. ALZ-801 has carried FDA Fast Track designation since 2017.

Alzheon's business model is currently pre-revenue and built around advancing its pipeline toward U.S. commercialization of ALZ-801 in 2025, supported by a $100 million Series E (June 2024), a prior $50 million Series D (April 2022), and $51 million in grants from the National Institute on Aging. The company is constructing a U.S. direct sales and market access organization under a newly appointed Chief Commercial Officer with prior launch experience at Biogen, Genentech, J&J, and AstraZeneca. Revenue mechanics will rely on prescription pharmaceutical sales to healthcare providers and payers once approval is secured; pricing has not been publicly disclosed and no licensing revenue has been reported.

Alzheon firmographics

Firmographics
Name
Alzheon
Legal name
Alzheon, Inc.
Website
https://alzheon.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Alzheon is a clinical-stage biopharmaceutical company developing oral anti-amyloid oligomer small molecules, led by valiltramiprosate (ALZ-801) in Phase 3 for Early Alzheimer's disease in APOE4/4 homozygotes, preparing for a U.S. commercial launch.
Ownership category
akta.pro rank

Where Alzheon is headquartered

Location

Headquarters

HQ city
Framingham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alzheon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Alzheon plans to commercialize oral valiltramiprosate/ALZ-801 as a disease-modifying treatment for Alzheimer's disease following regulatory approval. Expected commercial launch in 2025 pending successful Phase 3 trial completion and NDA submission.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Alzheon product offering

Product offering

Core offering

Alzheon is developing valiltramiprosate/ALZ-801, an investigational oral anti-amyloid oligomer treatment for Early Alzheimer's disease, with initial focus on APOE4/4 homozygote patients. The product blocks formation of neurotoxic soluble beta amyloid oligomers through a novel enveloping molecular mechanism of action without binding to amyloid plaques. The company has completed Phase 3 APOLLOE4 testing and is preparing for potential regulatory approval and U.S. commercial launch.

Product overview

Alzheon is a clinical-stage biopharmaceutical company developing a portfolio of product candidates for Alzheimer's disease and other neurodegenerative disorders. The lead product is valiltramiprosate/ALZ-801, an oral anti-amyloid agent in Phase 3 development targeting neurotoxic beta amyloid oligomers in early Alzheimer's disease patients, particularly APOE4/4 homozygotes. The company also has ALZ-507 in Phase 1 development and maintains a discovery platform of small molecules using precision medicine approaches. The company is preparing for potential regulatory filings and commercialization of ALZ-801 with expected U.S. market launch in 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • Valiltramiprosate/ALZ-801 Valiltramiprosate/ALZ-801 is an investigational first-in-class oral anti-amyloid agent that blocks formation of neurotoxic soluble beta amyloid oligomers through a novel enveloping molecular mechanism of action, without binding to amyloid plaques or causing vasogenic brain edema. It is being developed as a disease-modifying treatment for Early Alzheimer's disease, with initial focus on patients homozygous for the APOE4/4 genotype who are 8-12 times more likely to develop AD. The oral tablet formulation crosses the blood-brain barrier efficiently and enables convenient at-home administration.
  • ALZ-507 ALZ-507 is an oral drug candidate in Phase 1 development for Alzheimer's disease that targets amyloid aggregation with an additional APOE4 corrector mechanism. It is designed for potential once-daily administration with improved safety and efficacy compared to existing anti-amyloid therapies.

Quantifiable outcome

  • 31% reduction in plasma P-tau181 at 24 months in Phase 2 trial
  • +3 more outcomes

Companies that use Alzheon

Customer profile

Segments3 records

Ideal customer profiles1 record

Alzheon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Alzheon partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Bellus HealthcoreTechnology or IntegrationALZ-801/valiltramiprosate was licensed from Bellus Health. The drug is an optimized prodrug of tramiprosate originally developed by Bellus Health.
  • EisaiminorStrategic or Co-development PartnerAt the AD/PD annual meeting, both companies presented data on treatments targeting high-risk Alzheimer's patients with APOE4 genetic profiles. Both focus on improving treatment options for genetically defined populations.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Alzheon competitors and assessment

Company assessment

Direct peers

  • Prothena: Clinical-stage biotechnology company developing protein immunotherapy approaches for Alzheimer's disease and other neurodegenerative disorders, including anti-amyloid antibodies. Comparable as a clinical-stage AD-focused biotech with overlapping target biology.
  • AC Immune: Clinical-stage biopharmaceutical company developing therapeutics for Alzheimer's disease and neurodegenerative disorders, with both small molecule and vaccine approaches. Comparable as a clinical-stage AD biotech with multiple pipeline assets targeting amyloid and tau.
  • Cognition Therapeutics: Clinical-stage company developing CT1812, an oral small molecule for Alzheimer's disease and other neurodegenerative disorders. Comparable as a similarly-staged AD biotech focused on synaptic and oligomer-related mechanisms.
  • Anavex Life Sciences: Clinical-stage biotechnology company developing blarcamesine (ANAVEX2-73), an oral small molecule for Alzheimer's disease and other neurodegenerative disorders. Directly comparable as a clinical-stage CNS biotech with similar development profile and oral small molecule approach.
  • Cassava Sciences: Clinical-stage biotechnology company developing simufilam, an oral small molecule for Alzheimer's disease. Directly comparable to Alzheon as a similarly-sized private/public clinical-stage AD therapeutics company targeting oral disease-modifying mechanisms.

Emerging players

  • Vigil Neuroscience: Clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases, with a focus on TREM2 agonist and microglia-targeting approaches. Comparable as an emerging clinical-stage neurodegeneration biotech with similar stage and target indication space.
  • Denali Therapeutics: Clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's, with a focus on small molecules and biologics that cross the blood-brain barrier. Comparable as an emerging clinical-stage CNS biotech with similar BBB-penetration and neurodegeneration focus.

Broad incumbents

  • Biogen: Large biopharmaceutical company with marketed Alzheimer's therapies including Aduhelm and co-developed Leqembi. Comparable as the established incumbent in the AD therapeutics space, against which Alzheon's oral therapy must differentiate.
  • Eli Lilly: Global pharmaceutical company that markets Kisunla (donanemab) for early symptomatic Alzheimer's disease. Comparable as a broad incumbent in AD therapeutics with an approved anti-amyloid antibody competing with Alzheon's oral approach.
  • Eisai: Global pharmaceutical company that co-developed and markets Leqembi (lecanemab) for Alzheimer's disease. Comparable as the leading commercialized AD therapeutics incumbent and a co-development partner cited in Alzheon's industry engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Alzheon social profiles

Digital presence

Alzheon compliance and trust

Trust signal

Compliance1 record

Alzheon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alzheon leadership team

Management profile

Number of profiles

Profiles8 records

Alzheon funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alzheon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzheon

What does Alzheon do?

Alzheon is developing valiltramiprosate/ALZ-801, an investigational oral anti-amyloid oligomer treatment for Early Alzheimer's disease, with initial focus on APOE4/4 homozygote patients. The product blocks formation of neurotoxic soluble beta amyloid oligomers through a novel enveloping molecular mechanism of action without binding to amyloid plaques. The company has completed Phase 3 APOLLOE4 testing and is preparing for potential regulatory approval and U.S. commercial launch.

Is Alzheon a public or private company?

Alzheon is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alzheon founded?

Alzheon was founded in 2013. It employs 11 to 50 people.

Where is Alzheon based?

Alzheon is headquartered in Framingham, United States, in the North America region.

How does Alzheon make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Alzheon's main competitors?

Direct peers on record are Prothena, AC Immune, Cognition Therapeutics, Anavex Life Sciences and Cassava Sciences. Emerging players are Vigil Neuroscience and Denali Therapeutics. Broad incumbents are Biogen, Eli Lilly and Eisai.

Does Alzheon have an API?

No public API is recorded for Alzheon.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyAlzheon launches second Phase 3 trial for Alzheimer’s drugAlzheon launched ORION-E4, a second Phase 3 trial of oral valiltramiprosate/ALZ-801. The trial is designed to confirm benefits seen in the APOLLOE4 mild cognitive impairment subgroup.WikipediaValiltramiprosateValiltramiprosate is an investigational new drug developed by Alzheon to treat early Alzheimer's disease. Phase III results published in late 2025 suggested it offered some benefit to certain patients genetically predisposed to Alzheimer's, primarily when taken before dementia developed.Longevity.TechnologyAlzheon’s oral Alzheimer’s pill shows blood marker dropAlzheon published peer-reviewed data showing its oral pill valiltramiprosate lowers the blood marker p-tau217 in Alzheimer's patients, with levels significantly reduced at weeks 26, 52, and 78. The drop correlated with slower memory and brain decline, and a second marker, neurofilament light chain, remained flat. The company plans its next Phase 3 trial.Longevity.TechnologyAlzheon reports Phase 3 win with an Alzheimer’s treatment targeted at high-risk genetic carriersAlzheon reported Phase 3 data for valiltramiprosate/ALZ-801 in APOE4 carriers with early Alzheimer's, showing sustained reductions in plasma p-tau217 and p-tau217/Aβ42 ratio. The changes correlated with less cognitive decline, reduced hippocampal atrophy, and preserved cortical thickness. The company plans further Phase 3 work in this population.Longevity.TechnologyFresh analyses reshape Alzheon’s oral Alzheimer’s drugClinical-stage biopharma Alzheon presented nine new analyses at the Alzheimer's Association International Conference (AAIC) in London, suggesting its oral Alzheimer's therapy valiltramiprosate (ALZ-801) may benefit patients with mild cognitive impairment and those carrying two copies of the APOE4 gene, despite its Phase 3 trial failing to meet its primary endpoint. The analyses showed encouraging findings including better hippocampal preservation, reductions in plasma p-tau217 biomarker, and no symptomatic amyloid-related imaging abnormalities during up to four years of treatment, positioning the drug as a potential oral maintenance option following anti-amyloid antibody therapies. Regulators will ultimately decide approval based on the totality of evidence, but the findings highlight a broader shift toward precision medicine approaches that target specific patient subgroups rather than treating all early-Alzheimer's patients uniformly.Longevity.TechnologyNew data shows Alzheon’s oral Alzheimer’s drug reduces brain swelling and preserves memoryAlzheon announced it will present nine posters at the Alzheimer's Association International Conference 2026 in London from July 12 to 15, showcasing expanded analyses from its Phase 3 APOLLOE4 trial and long-term extension cohorts for its investigational oral agent Valiltramiprosate (ALZ-801). The data demonstrate neurovascular protection, lower rates of amyloid-related imaging abnormalities compared to placebo, preservation of hippocampal microstructure, reductions in plasma p-tau217, and clinically meaningful benefits on cognition and brain volume in the pre-specified mild cognitive impairment subgroup, despite the Phase 3 trial not meeting its primary endpoint.BioSpaceAlzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in LondonAlzheon will present nine posters on valiltramiprosate at AAIC 2026, covering Phase 3 and extension data from APOE4/4 Alzheimer's patients. The presentations highlight neurovascular protection, lower ARIA rates, and sustained cognitive and brain volume benefits. The company positions the oral agent as a potential first-in-class disease-modifying therapy.Business Wire BlogAlzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved SAlzheon, Inc. announced the dosing of the first subject in a Phase 1 clinical trial for ALZ-507, an investigational oral drug candidate targeting Alzheimer's disease pathology. The therapy is designed to inhibit amyloid aggregation and function as an APOE4 corrector, with potential benefits including once-daily administration and improved tolerability. Findings from this safety and pharmacokinetic study will guide dose selection for subsequent Phase 2 trials involving patients with Alzheimer's disease.PharmiWeb.comAlzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved SAlzheon, Inc. announced the dosing of the first cohort of healthy volunteer subjects in a Phase 1 single and multiple ascending dose clinical trial of ALZ-507, a novel investigational oral drug candidate for Alzheimer's disease. ALZ-507 is designed as a next-generation oral treatment targeting soluble amyloid oligomer formation, with an additional mechanism as an APOE4 corrector, offering potential advantages including once-daily dosing. The Phase 1 study will assess safety, tolerability, and pharmacokinetics to guide dose selection for subsequent Phase 2 studies in Alzheimer's disease, Down syndrome-associated AD, and cerebral amyloid angiopathy patients.BioSpaceEisai, Alzheon Drill Down on Promising Results in High-Risk Alzheimer’s SubsetAt the AD/PD annual meeting in Copenhagen, Eisai presented real-world data on Leqembi showing that APOE4 homozygotes—a patient subgroup excluded by some regulators—experienced brain bleeds (ARIA) at lower rates (21.2%) than observed in clinical trials (45%), with 76% of patients at the same or improved disease stage after an average follow-up of 491 days. Alzheon also presented updated results for its drug candidate valiltramiprosate, showing sustained reductions in the p-tau-217 biomarker through four years of follow-up in mild cognitive impairment patients and notably lower ARIA-H rates compared to placebo. Both companies are positioning their findings to support broader use of anti-amyloid therapies in APOE4 carriers, who carry heightened Alzheimer's risk but have faced treatment restrictions due to safety concerns.